A research paper on AI-driven drug discovery by SAKURA internet and COGNANO was accepted by NeurIPS 2024, a prestigious AI conference

Contributed by: Business Wire

Images

Overview of Research (Graphic: Business Wire)

Business Wire embedded0

Tags

Research

Pharmaceutical

Other Natural Resources

Technology

Infectious Diseases

Natural Resources

Artificial Intelligence

Health Technology

Science

COVID-19

Biotechnology

Health

AI, pharmaceuticals

More Like This

PR Newswire associated0

Cognizant Unveils Advanced Artificial Intelligence Lab to Accelerate AI Research and Innovation

Unlocking the Power of Large Language Models: From Neural Network Basics to Biopharma Industry Transformation

PR Newswire associated0

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Fugaku-LLM is now a part of Samba-1. Photo featuring Rodrigo Liang, CEO, SambaNova Systems; Matsuoka Satoshi, Director of the RIKEN Center for Computational Science; Marshall Choy, SVP of Product, SambaNova Systems; Toshinori Kujiraoka, General Manager of APAC, SambaNova Systems. (Photo: Business Wire)

SambaNova Announces That Fugaku-LLM Is Now a Part of Samba-1

Argonne National Laboratory is expanding the lab’s AI infrastructure with the deployment of SambaNova Suite (Graphic: Business Wire)

Argonne National Laboratory Deploys a New SambaNova Inference-Optimized Cluster to Support AI-Driven Science

PR Newswire associated0

Cognizant to apply generative AI to enhance drug discovery for pharmaceutical clients with NVIDIA BioNeMo

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy